Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Equity Average: 2011-2025

Historic Equity Average for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to $471.3 million.

  • Ani Pharmaceuticals' Equity Average fell 2.49% to $471.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $471.3 million, marking a year-over-year decrease of 2.49%. This contributed to the annual value of $458.9 million for FY2024, which is 0.02% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Equity Average stood at $471.3 million for Q3 2025, which was up 10.19% from $427.7 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Equity Average high stood at $483.3 million for Q3 2024, and its period low was $191.7 million during Q3 2021.
  • Over the past 3 years, Ani Pharmaceuticals' median Equity Average value was $453.9 million (recorded in 2024), while the average stood at $438.7 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Equity Average skyrocketed by 107.25% in 2022 and then decreased by 14.88% in 2025.
  • Ani Pharmaceuticals' Equity Average (Quarterly) stood at $289.6 million in 2021, then surged by 38.68% to $401.6 million in 2022, then climbed by 17.51% to $472.0 million in 2023, then dropped by 3.11% to $457.3 million in 2024, then declined by 2.49% to $471.3 million in 2025.
  • Its last three reported values are $471.3 million in Q3 2025, $427.7 million for Q2 2025, and $411.1 million during Q1 2025.